Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: A double blind, randomized, placebo-controlled study

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 559-563

  Dazzi, C ^a,c   Cariello, A ^a   Giovanis, P ^a   Monti, M ^a   Vertogen, B ^a   Leoni, M ^a   Tienghi, A ^a   Turci, D ^a   Rosti, G ^a   Nanni, O ^b   Rondoni, C ^a   Marangolo, M ^a  

^a City Hospital   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

GM CSF; Mouthwash; Mucositis; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MITOXANTRONE; OPIATE; PLACEBO; SARCOLYSIN; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CENTER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MOUTH MUCOSA; MOUTHWASH; MUCOSA INFLAMMATION; NEUTROPHIL; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STATISTICAL ANALYSIS; STOMATITIS; VISUAL ANALOG SCALE; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLACEBOS; SEVERITY OF ILLNESS INDEX; STOMATITIS; TREATMENT OUTCOME;

EID: 0037481761     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg177     Document Type: Article

References (30)

1. Woo SB, Sonis ST, Monopoli MM, Sonis A. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612-1617.
2. Pico JL, Avila-Garavito A, Naccachie P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998; 3: 446-451.
3. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001; 27 (Suppl 2): S3-S11.
4. Heimdahal A, Mattson T, Dahlof G et al. The oral cavity as a port for early infection in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1989; 68: 711-716.
5. Davidson JM, Broadley KN. Manipulation of the wound healing process with fibroblast growth factor. Ann N Y Acad Sci 1991; 638: 307-315.
6. Rubbia L, Sappino AC, Gabbiani G. Locally applied GM-CSF induces the accumulation of alpha-smooth muscle actin containing myofibroblasts. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60: 73-82.
7. Robson M, Kucukcelebi A, Carp SS et al. Effects of granulocyte-macrophage colony-stimulating on wound contraction. Eur J Clin Microbiol Infect Dis 1994; 3 (Suppl 2): S41-S46.
8. Jyung RW, Wu L, Pierce GF, Mustoe TA. Granulocyte macrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing. Surgery 1994; 115: 325-334.
9. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-1422.
10. Chi KH, Chen CH, Chan WK et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995; 13: 2620-2628.
11. Karthaus M, Rosenthal C, Huebner G et al. Effect of topical oral G-CSF on oral mucositis: a randomized placebo controlled trial. Bone Marrow Transplant 1998; 22: 781-785.
12. National Cancer Institute. Common Toxicity Criteria [online] (2003) http://ctep.cancer.gov/reporting/ctc.html.
13. Taylor KM, Jagannath S, Spitzer G et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7: 1791-1799.
14. Hermann F, Schulz G, Weiser M et al. Effect of granulocyte-macrophage colony stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 1990; 88: 619-624.
15. Nemunaitis J, Rosenfeld CS, Ash R et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949-954.
16. Atkinson K, Biggs JC, Downs K et al. GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust NZ J Med 1991; 21: 686-692.
17. Ovilla-Martinez R, Rubio ME, Borbolla JR et al. GM-CSF as treatment for mucositis in BMT patients. Blood 1994; 84: 10 (Abstr 2853).
18. Haus U, Quietzsch D, Faerber L et al. Effect of rh-granulocyte-macrophage colony-stimulating factor (GM-CSF) on oral mucositis. Ann Hematol 1996; 73 (Suppl 2): A51.
19. Cartee L, Petros WP, Rosner GL et al. Evaluation of GM-CSF mothwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose ranging study. Citokine 1995; 7: 471-477.
20. van der Lelie H, Thomas BLM, van Oers RHJ et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001; 80: 150-154.
21. Ferretti GA, Ash RC, Brown AT et al. Control of acute mucositis and candidiasis in marrow transplantation: a prospective double blind trial of chlorhexidine gluconate oral rinse. Bone Marrow Transplant 1988; 3: 483-493.
22. Ferretti GA, Hansen IA, Whittenburg K et al. Therapeutic use of chlorhexidine in bone marrow transplant patients: case studies. Oral Surg Oral Med Oral Pathol 1987; 63: 683-687.
23. Wahlin YB. Effects of chlorhexidine mouth rinse on oral health in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 1989; 68: 279-287.
24. Weisdorf DJ, Bostrom B, Raether D et al. Oropharingeal mucositis complicating bone marrow transplantation: prognostic factor and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989; 4: 89-95.
25. Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000; 110: 300-307.
26. Awidi A, Homsi U, Kakail RI et al. Double-blind, placebo-controlled cross over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. Eur J Cancer 2001; 37: 2010-2014.
27. Cohen G, Elad S, Or R et al. The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Dis 1997; 3: 243-246.
28. Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000; 34: 300-303.
29. Zeeh JM, Procaccino F, Hoffmann P et al. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 1996; 110: 1077-1083.
30. Schwerkoske J, Schwartzberg L, Weaver CH et al. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega® (rhIL-11; Oprelvelkin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). Proc Am Soc Clin Oncol 1999; 18: 584a (Abstr 2256).